keyword
MENU ▼
Read by QxMD icon Read
search

Pemetrexed

keyword
https://www.readbyqxmd.com/read/28229122/pemetrexed-induced-eccrine-squamous-syringometaplasia-manifesting-as-pseudocellulitis-in-a-patient-with-non-small-cell-lung-cancer
#1
Adinia Santosa, MeiQi May Liau, Kong Bing Tan, Lixian Chris Tan
No abstract text is available yet for this article.
January 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28222073/a-phase-i-study-of-intravenous-and-oral-rucaparib-in-combination-with-chemotherapy-in-patients-with-advanced-solid-tumours
#2
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, L Rhoda Molife, James Spicer, Veronique Dieras, Patricia Roxburgh, Heidi Giordano, Sarah Jaw-Tsai, Sandra Goble, Ruth Plummer
BACKGROUND: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. METHODS: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1-14) combined with carboplatin (day 1) in 21-day cycles...
February 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28218046/thyroid-transcription-factor-1-expression-is-associated-with-outcome-of-patients-with-non-squamous-non-small-cell-lung-cancer-treated-with-pemetrexed-based-chemotherapy
#3
Ondrej Fiala, Milos Pesek, Jana Skrickova, Vitezslav Kolek, Frantisek Salajka, Marcela Tomiskova, Monika Satankova, Juraj Kultan, Jana Kuliskova, Martin Svaton, Michal Hrnciarik, Karel Hejduk, Renata Chloupkova, Ondrej Topolcan, Helena Hornychova, Marketa Nova, Ales Ryska, Jindrich Finek
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28212999/meta-analysis-examining-impact-of-age-on-overall-survival-with-pemetrexed-for-the-treatment-of-advanced-non-squamous-non-small-cell-lung-cancer
#4
Luis G Paz-Ares, Annamaria Zimmermann, Tudor Ciuleanu, Paul A Bunn, Belen San Antonio, Jonathan Denne, Nancy Iturria, William John, Giorgio V Scagliotti
OBJECTIVE: In clinical practice, elderly patients are often undertreated relative to younger patients. This meta-analysis was designed to determine whether older patients with non-squamous non-small cell lung cancer (NSCLC) could derive an overall survival (OS) benefit from pemetrexed treatment comparable to that experienced by younger patients in the first-line, second-line, or maintenance settings. METHODS: Data from 2671 patients with non-squamous NSCLC participating in four pemetrexed phase III studies were included in a meta-analysis using a random-effects model...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28210100/the-cost-effectiveness-of-a-nsclc-patient-assistance-program-for-pemetrexed-maintenance-therapy-in-people-s-republic-of-china
#5
Qiang Shi, Shanlian Hu, Wesley E Furnback, Gregory F Guzauskas, Jiejing Shen, Bruce Cm Wang
BACKGROUND: Eli Lilly and the China Primary Health Care Foundation are currently implementing a patient assistance program (PAP) in China, which allows first-line nonsquamous non-small-cell lung cancer (NSCLC) patients who complete four cycles of pemetrexed induction therapy to receive free, continuous pemetrexed maintenance therapy. OBJECTIVE: To estimate the cost-effectiveness of pemetrexed maintenance therapy vs basic standard care (BSC) and the economic impacts of providing a PAP for pemetrexed maintenance therapy to NSCLC patients who have completed pemetrexed induction therapy in a Chinese health care setting...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28203304/muscle-spasms-an-unexpected-adverse-drug-reaction-of-pemetrexed
#6
REVIEW
Hendrika J A de Rouw, Naomi T Jessurun, Lucie J P Masen-Poos, Hieronymus J Derijks
In this report we describe a 53-year-old woman with advanced non-small cell lung cancer, treated with pemetrexed and cisplatin combination therapy, followed by pemetrexed monotherapy. The patient developed severe muscle spasms at least twice, shortly after administration of pemetrexed monotherapy. A possible explanation for this observation is that in combination with cisplatin therapy, the patient was hyperhydrated before administration to promote renal excretion and reduce toxicity. Pemetrexed is also renally excreted, which supports the finding that toxicity did not occur when the patient was hyperhydrated...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28197626/kdm6a-and-kdm6b-altered-expression-in-malignant-pleural-mesothelioma
#7
Sian Cregan, Maeve Breslin, Gerard Roche, Sigrid Wennstedt, Lauren MacDonagh, Cinaria Albadri, Yun Gao, Kenneth J O'Byrne, Sinead Cuffe, Stephen P Finn, Steven G Gray
Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the pleura primarily associated with prior exposure to asbestos. The current standard of care for patients suffering from MPM is a combination of cisplatin and pemetrexed (or alternatively cisplatin and raltitrexed). Most patients, however, die within 24 months of diagnosis. New therapies are therefore urgently required for this disease. Inflammation is thought to be a key element in the pathogenesis of MPM, and recently Kdm6 family members (Kdm6a and Kdm6b) have been identified as playing important roles in inflammatory processes...
March 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28191799/switch-maintenance-tyrosine-kinase-inhibitors-in-egfr-mutation-positive-metastatic-non-squamous-nsclc-experience-from-the-real-world
#8
Ayinash Pandey, V Noronha, A Joshi, K Prabhash
BACKGROUND: Induction pemetrexed platin doublet is the standard of care in locally advanced and metastatic non squamous NSCLC. Maintenance TKI has been successfully explored to sustain benefit achieved after induction therapy especially in EGFR mutation positive NSCLC. The aim of this study is to evaluate outcomes with maintenance TKI in EGFR mutation positive metastatic non squamous NSCLC after induction pemetrexed-platin doublet. The objective is to calculate progression freesurvival rate, overall survival rate and factors affecting outcomes...
September 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28185792/randomized-phase-iii-study-of-docetaxel-plus-cisplatin-versus-pemetrexed-plus-cisplatin-as-first-line-treatment-of-nonsquamous-non-small-cell-lung-cancer-a-trail-trial
#9
Cheol-Kyu Park, In-Jae Oh, Kyu-Sik Kim, Yoo-Duk Choi, Tae-Won Jang, Youn-Seup Kim, Kwan-Ho Lee, Kyeong-Cheol Shin, Chi Young Jung, Sei-Hoon Yang, Jeong-Seon Ryu, Seung-Hun Jang, Seung-Soo Yoo, Suk-Joong Yong, Kye Young Lee, Kwang-Ho In, Min-Ki Lee, Young-Chul Kim
INTRODUCTION: To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non-small-cell lung cancer. MATERIALS AND METHODS: A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m(2) with either docetaxel 60 mg/m(2) (n = 71) or pemetrexed 500 mg/m(2) (n = 77) for ≤ 4 cycles...
January 11, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28179355/cyfra-21-1-as-a-predictive-marker-for-non-small-cell-lung-cancer-treated-with-pemetrexed-based-chemotherapy
#10
Kazuki Sone, Tetsuya Oguri, Makoto Nakao, Yusuke Kagawa, Ryota Kurowaka, Hiromi Furuta, Satoshi Fukuda, Takehiro Uemura, Osamu Takakuwa, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Hidefumi Sato, Hideki Muramatsu, Akio Niimi
BACKGROUND: Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative. PATIENTS AND METHODS: We retrospectively screened 100 chemotherapy-naïve patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA)...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28179309/importance-of-bevacizumab-maintenance-following-combination-chemotherapy-in-human-non-small-cell-lung-cancer-xenograft-models
#11
Nobuyuki Ishikura, Mieko Yanagisawa, Mariko Noguchi-Sasaki, Toshiki Iwai, Keigo Yorozu, Mitsue Kurasawa, Masamichi Sugimoto, Kaname Yamamoto
BACKGROUND: Bevacizumab in combination with chemotherapeutics has shown significant survival benefit in clinical studies in patients with non-small cell lung cancer (NSCLC). Since bevacizumab was administered as standard treatment until disease progression, the importance of bevacizumab during the maintenance phase was not prospectively investigated in these studies. MATERIALS AND METHODS: Three human NSCLC cell line xenograft models were used to investigate antitumor effect of bevacizumab and tumor microvessel density (MVD) was analyzed...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28174382/-persistent-chemotherapy-induced-hiccups-successfully-treated-with-pregabalin
#12
Kyoko Nakanishi, Kumi Sugiyama, Yasushi Abe, Tetsushi Endo, Yoshinobu Ohsaki
A 62-year-old male was diagnosed with large cell lung cancer(c-Stage IV)based on pathological examination of an anterior chest tumor. He received chemotherapy with cisplatin, pemetrexed, and bevacizumab. He suffered from persistent hiccups from day 2 of the first course of chemotherapy. He was unsuccessfully treated with chlorpromazine, shakuyakukanzoto, and gabapentin. Therefore, we administered pregabalin to him, and his hiccups subsided immediately. To prevent hiccups, he subsequently took pregabalin along with his chemotherapy regimen, and was able to receive 4 courses of chemotherapy without persistent hiccups...
January 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28168189/historical-evolution-of-second-line-therapy-in-non-small-cell-lung-cancer
#13
REVIEW
Chiara Lazzari, Alessandra Bulotta, Monika Ducceschi, Maria Grazia Viganò, Elena Brioschi, Francesca Corti, Luca Gianni, Vanesa Gregorc
Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who depend on oncogenic molecular alterations for their malignant phenotype. Despite the survival improvement achieved with first-line chemotherapy, about 30% of patients do not obtain a tumor response. Moreover, those patients, initially sensitive to treatment, acquire resistance and develop tumor progression after a median of about 5 months...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28164096/gefitinib-with-pemetrexed-as-first-line-therapy-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-with-activating-epidermal-growth-factor-receptor-mutations
#14
EDITORIAL
Shinkyo Yoon, Dae Ho Lee, Sang-We Kim
No abstract text is available yet for this article.
January 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28158568/pemetrexed-related-interstitial-lung-disease-reported-from-post-marketing-surveillance-malignant-pleural-mesothelioma-non-small-cell-lung-cancer
#15
Keisuke Tomii, Terufumi Kato, Masashi Takahashi, Satoshi Noma, Yoichiro Kobashi, Sotaro Enatsu, Sumiko Okubo, Noriko Kobayashi, Shoji Kudoh
No abstract text is available yet for this article.
February 2, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28158216/non-steroidal-anti-inflammatory-drugs-induce-severe-hematologic-toxicities-in-lung-cancer-patients-receiving-pemetrexed-plus-carboplatin-a-retrospective-cohort-study
#16
Hitoshi Kawazoe, Akiko Yano, Yuri Ishida, Kenshi Takechi, Hitoshi Katayama, Ryoji Ito, Yoshihiro Yakushijin, Toshihide Moriguchi, Mamoru Tanaka, Akihiro Tanaka, Hiroaki Araki
PURPOSE: As the major toxicity induced by pemetrexed plus carboplatin is severe hematologic toxicities, the aim of this study was to determine the risk factors for severe hematologic toxicities in lung cancer patients. METHODS: We retrospectively investigated data from lung cancer patients who had received pemetrexed plus carboplatin, with or without bevacizumab. This observational study was carried out at Ehime University Hospital using electronic medical records dating from July 2009 to March 2015...
2017: PloS One
https://www.readbyqxmd.com/read/28153512/paclitaxel-releasing-mesenchymal-stromal-cells-inhibit-in-vitro-proliferation-of-human-mesothelioma-cells
#17
Francesco Petrella, Valentina Coccè, Carla Masia, Martina Milani, Emanuela Omodeo Salè, Giulio Alessandri, Eugenio Parati, Francesca Sisto, Francesca Pentimalli, Anna T Brini, Augusto Pessina, Lorenzo Spaggiari
INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare fatal asbestos-related malignancy originating in the mesothelial cells of the pleura. A platinum-based doublet containing a third-generation antifolate is the front-line standard of care whilst there are no approved second-line treatments for MPM which remains a disease setting to test the efficacy of new therapeutic agents. METHODS: Bone marrow mesenchymal stromal cells (BM-MSCs) were loaded with pemetrexed (PMX) and paclitaxel (PTX) according to a standardized procedure...
March 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28149755/state-of-the-art-of-chemotherapy-for-the-treatment-of-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#18
REVIEW
Alessandro Inno, Vincenzo Di Noia, Ettore D'Argento, Alessandra Modena, Stefania Gori
Chemotherapy is the mainstay of treatment of advanced non-small cell lung cancer (NSCLC) without molecular drivers. Despite a low penetration of central nervous system (CNS), chemotherapy drugs demonstrated encouraging activity against CNS metastases from NSCLC. Based on the available data, chemotherapy should be considered as an important part of the multidisciplinary treatment of CNS metastases. Particularly, platinum-based regimens represent the most active combinations and pemetrexed is associated with a meaningful clinical benefit for patients with non-squamous histology...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149588/pemetrexed-induced-radiation-recall-dermatitis-in-a-patient-with-lung-adenocarcinoma-case-report-and-literature-review
#19
Jin Ge, Vivek Verma, Andrew Hollander, Corey Langer, Charles B Simone
Radiation recall dermatitis (RRD) is an inflammatory reaction in a previously irradiated field subsequent to the administration of pharmacologic or promoting agents. Herein, we describe a 47-year-old man with NSCLC who was treated with radiotherapy and pemetrexed-based chemotherapy three years prior to developing RRD upon resumption of pemetrexed-based chemotherapy. RRD with pemetrexed is rare and consists of five cases reported thus far. Although RRD is a rare phenomenon, it should be considered in any patient with dermatologic reactions that occur at the site of previous exposure to radiation therapy...
December 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28141932/an-expanded-portfolio-of-survival-metrics-for-assessing-anticancer-agents
#20
Jennifer Karweit, Srividya Kotapati, Samuel Wagner, James W Shaw, Steffan W Wolfe, Amy P Abernethy
OBJECTIVES: With the introduction of more effective anticancer agents that prolong survival, there is a need for new methods to define the clinical value of treatments. The objective of this preliminary qualitative and quantitative analysis was to assess the utility of an expanded portfolio of survival metrics to differentiate the value of anticancer agents. STUDY DESIGN: A literature review was conducted of phase 3 trial data, reported in regulatory submissions within the last 10 years of agents for 6 metastatic cancers (breast cancer, colorectal cancer [CRC], melanoma, non-small cell lung cancer [NSCLC], prostate cancer [PC], and renal cell cancer [RCC])...
January 2017: American Journal of Managed Care
keyword
keyword
8879
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"